Webinar to present findings from unique multidisciplinary research trials on lactose blending and filling

Recent trend suggests that newer developed DPI formulations are combination of ternary mixtures including Lactose, magnesium stearate and APIs. We will focus on practical insights into lactose-based DPI formulations, with and without magnesium stearate. The market for this kind of formulations is rapidly growing. However, the successful delivery of the active ingredient into the lungs depends on numerous interconnected factors during the production process. In order to gain a better understanding of how these changes can affect one another, three leading companies with complementary areas of expertise – covering lactose, blending and filling – have joined forces to conduct a unique multidisciplinary study. DFE, Harro Höfliger and Hosokawa will be presenting in a series of events the key insights from their research trials to interested parties during this webinar.


Harry Peters
DFE Pharma

Harry Peters is working as a Senior Product Application Specialist Inhalation at DFE Pharma Germany. He has studied Food Technology and worked at Solvay Pharmaceuticals as product developer for oral solid dosage forms. After this work experience he started working for Sensient Technologies in the Research and Development department.

He was responsible for the development of natural colour formulations and was application specialist for colours in the food and pharmaceutical industry. Since 2003 he joined DFE Pharma. He has worked in different roles in the R&D department of DFE Pharma and contributed to customer projects who have launched of dry powder inhaler formulations onto the market. He has published various articles on functionality of lactose in dry powder inhalers and characterization of lactose for inhalation.

Dr Mohit Mehta
Harro Höfliger

Dr Mohit Mehta is Director DPI Consulting at Harro Hofliger, Germany. He obtained a PhD in Pharmaceutical technology from Mumbai university (2013). Subsequently, he joined Respiratory center of excellence, Cipla R&D and gained extensive experience on respiratory API micronization, particle engineering and formulation development of dry powder inhalers.

He led the team in successful development of Dry powder inhalers for key regulated markets. Later he worked with DFE Pharma, Germany, where he was responsible as technical lead and customer support for development of customized Inhalation grade lactose and in exploring new excipients for biologics. Dr Mohit Mehta recently joined Harro Hofliger, where he is responsible for managing external consultancy projects related to product development of novel drug delivery systems and dry powder inhalers.

Olukayode I. Imole (Kay)
Hosokawa Micron B.V.

Olukayode I. Imole (Kay) currently works as a process technologist in the research and development department of Hosokawa Micron B.V., The Netherlands. Prior to this, he was a post-doctoral research fellow in the Multi-Scale Mechanics group, chaired by Prof. Stefan Luding at the University of Twente The Netherlands.

In 2014, he received his PhD in computational sciences and engineering (focus on Particle and Powder Technology) from the same University as a Marie Curie fellow. He also received a DAAD fellowship for the completion of his MSc degree in quality, safety and environment at the Otto-von-Guericke University , Magdeburg, Germany, where he worked on the synthesis of nanoparticles. With a background in mechanical engineering, his current research interests spans through all process aspects of (pharmaceutical) mixing, drying and agglomeration.